Vergo Pharma Research Laboratories Private Limited

Vergo Pharma Research Laboratories Private Limited, incorporated on August 10, 2010, is a private, non-government company based in Panaji, Goa, India. The company is registered with the Corporate Identification Number (CIN) U73200GA2010PTC006462. Its authorized and paid-up capital stands at ₹27.01 crore (approximately $3.6 million USD). The registered office is located at Keni Building, Dr. Dada Vaidya Road, Panaji, Goa, India, 403001.

Vergo Pharma specializes in the research and development of pharmaceutical formulations, focusing on generic drugs. The company offers a comprehensive suite of services, including formulation development, contract manufacturing, and clinical bioavailability/bioequivalence (BA/BE) studies. These services cater to global clients and partners, particularly in regulated markets. As of March 2026, Vergo Pharma employs over 200 professionals, including scientists, researchers, and support staff.

Vergo Pharma operates a cGMP-compliant manufacturing facility located in the Verna Industrial Estate, Goa, India. This facility specializes in the production of oral solid dosage forms, such as tablets and capsules, and has a manufacturing capacity of approximately 500 million tablets per annum. The plant is approved by regulatory bodies including the UK's MHRA, the World Health Organization (WHO), and the Therapeutic Goods Administration (TGA) of Australia.

The leadership team at Vergo Pharma comprises experienced professionals with diverse expertise in the pharmaceutical industry. Prasad Vassudev Keni serves as the Managing Director, overseeing the company's strategic direction and operations. Vini Prasad Keni holds the position of Director, contributing to the company's governance and decision-making processes. Kashyap Prasad Keni, also a Director, leads business development initiatives, focusing on expanding the company's market presence. Amol Shivaji Borkar serves as the Chief Financial Officer, managing financial operations and ensuring fiscal responsibility.

Vergo Pharma has established a presence in several regulated markets, including the United States, European Union, United Kingdom, and Australia. The company's manufacturing facility in Goa holds approvals from the UK's MHRA, WHO, and TGA Australia, facilitating market access in these regions. Additionally, Vergo Pharma has commercialized 12 products for the UK market, demonstrating its capability to meet stringent regulatory standards.

Vergo Pharma has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, enhances its ability to penetrate these markets. These certifications enable Vergo Pharma to supply products to countries that recognize WHO prequalified manufacturers, thereby broadening its global footprint.

Vergo Pharma's geographic strategy involves a balanced approach, targeting both regulated and emerging markets to diversify its revenue streams. The company's focus on obtaining approvals from regulatory bodies such as the MHRA, WHO, and TGA Australia underscores its commitment to quality and compliance, which is crucial for accessing regulated markets. Simultaneously, Vergo Pharma's WHO prequalification and EU GMP certifications position it favorably to serve emerging markets, mitigating concentration risk and enhancing its strategic direction.

As of March 2026, Vergo Pharma's manufacturing facility in Goa is not registered with the U.S. Food and Drug Administration (FDA). The company has not filed any Abbreviated New Drug Applications (ANDAs) or Drug Master Files (DMFs) with the FDA, and there is no available information regarding FDA inspections or observations. This indicates that Vergo Pharma currently does not supply pharmaceutical products to the U.S. market.

Vergo Pharma's manufacturing facility holds certifications from the World Health Organization (WHO) and the European Union Good Manufacturing Practice (EU GMP). These certifications validate the company's adherence to international quality standards, enabling it to supply pharmaceutical products to markets that recognize WHO prequalified manufacturers and EU GMP-compliant facilities.

Vergo Pharma's manufacturing facility in Goa is approved by the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The facility holds a valid manufacturing license issued by the CDSCO, ensuring compliance with Indian pharmaceutical regulations. Additionally, the company has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), authorizing it to export pharmaceutical products to various international markets.

As of March 2026, there are no publicly available records indicating that Vergo Pharma has received any Form 483 observations, warning letters, or import alerts from regulatory authorities such as the FDA, WHO, or CDSCO. This suggests that the company maintains a clean regulatory record, reflecting its commitment to compliance and quality standards.

In the generic pharmaceutical sector, Vergo Pharma faces competition from both domestic and international companies. Key competitors include established Indian pharmaceutical firms with extensive product portfolios and global distribution networks. Vergo Pharma differentiates itself through its specialized services, including formulation development, contract manufacturing, and clinical BA/BE studies, catering to both regulated and emerging markets. The company's certifications from WHO and EU GMP further enhance its competitive position by ensuring product quality and regulatory compliance.

Vergo Pharma's key differentiators include its integrated approach as a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), offering a comprehensive suite of services from formulation development to clinical studies. The company's cGMP-compliant manufacturing facility, approved by international regulatory bodies, underscores its commitment to quality. Additionally, Vergo Pharma's focus on both regulated and emerging markets allows it to leverage a diverse customer base, mitigating risks associated with market concentration.

Vergo Pharma's current strategic direction emphasizes growth in both generics and specialty pharmaceuticals, with a focus on expanding its presence in regulated markets through compliance with international standards. The company's integrated CDMO-CRO model positions it to offer end-to-end solutions to clients, enhancing its value proposition. Looking ahead, Vergo Pharma aims to strengthen its capabilities in biosimilars and Contract Development and Manufacturing Organization (CDMO) services, aligning with global industry trends and expanding its service offerings.

Vergo Pharma has demonstrated a consistent track record in pharmaceutical manufacturing, with a total export value of $2.1 million USD across 162 shipments from 2022 to 2026. The company's portfolio includes five products across five therapeutic categories, with the top five products accounting for 100% of its export value. This indicates a focused product strategy, which may offer advantages in quality control and operational efficiency. The company's adherence to international quality standards, as evidenced by its WHO prequalification and EU GMP certifications, further underscores its reliability as a supplier.

Importers should verify the following certifications when considering Vergo Pharma as a supplier:

• WHO Prequalification: Confirms that the company's products meet international quality standards recognized by the World Health Organization. Verification can be done through the WHO's official website or by contacting the company directly.

• EU GMP Certification: Indicates compliance with European Union Good Manufacturing Practice standards. This certification can be verified through the European Medicines Agency (EMA) or by contacting Vergo Pharma.

• FDA Registration: While Vergo Pharma is not currently registered with the U.S. Food and Drug Administration (FDA), importers should verify the FDA registration status of any pharmaceutical supplier. This can be done through the FDA's official website or by contacting the company directly.

When conducting due diligence on Vergo Pharma, consider the following steps:

• Verify Regulatory Certifications: Confirm the validity of WHO prequalification and EU GMP certifications through the respective regulatory bodies.

• Assess Financial Health: Review the company's financial statements for the latest fiscal year to evaluate profitability, revenue growth, and financial stability.

• Evaluate Product Portfolio: Analyze the company's product offerings, focusing on therapeutic categories, market share, and regulatory